A phase 1, double-blind, parallel, placebo-controlled, randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics, and acceptability of PC-1005 microbicide gel formulation in HIV-seronegative women

Trial Profile

A phase 1, double-blind, parallel, placebo-controlled, randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics, and acceptability of PC-1005 microbicide gel formulation in HIV-seronegative women

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs MIV 150/zinc acetate (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 17 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 19 Jul 2016 Results published in the JAIDS
    • 25 Feb 2016 Results (n=16) [pharmacodynamics study testing activity of CVLs collected 4h or 24h, against HIV only and HIV-1/HSV-2 co-infection in cervical mucosa] were presented at the 23rd Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top